Patents Examined by Pancham Bakshi
  • Patent number: 12011425
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: June 18, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xuri Gao, Jorden Kass, Hui Cao, Wei Li, Xiaowen Peng, Byung-Chul Suh, Yat Sun Or
  • Patent number: 12011500
    Abstract: Injectable compositions and methods of treating skin can help improve hydration, elasticity and/or texture of the skin. The compositions can be based on crosslinked hyaluronic acid matrices made with low molecular weight hyaluronic acids.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: June 18, 2024
    Assignee: Allergan Industrie, SAS
    Inventors: Pierre Lebreton, Olivier Guetta
  • Patent number: 11998530
    Abstract: Disclosed herein are a micelle comprising a benzimidazole-carbohydrate conjugate compound represented by the following chemical formula 1, a preparation method thereof, and use thereof as an anticancer agent or an antiviral agent comprising the same: in the above formula, R1, R2, R3 and X are the same as those defined in the disclosure and claims.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: June 4, 2024
    Assignee: BIOMETRIX TECHNOLOGY INC.
    Inventors: Taisun Kim, Keumsoo Song, Junghun Kim
  • Patent number: 11998558
    Abstract: The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: June 4, 2024
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, David Paul Kronlage
  • Patent number: 11998551
    Abstract: The present invention provides a composition comprising one or more deoxyribonucleosides for use in the treatment of a mitochondrial DNA depletion and/or multiple deletions syndrome provided that the syndrome is not caused by a defect in the deoxyribonucleoside triphosphate (dNTP) metabolism. With the use of the invention there is a recovery in mitochondrial DNA levels independently from the severity of the patient's disease, which confers a great therapeutic value to the invention.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: June 4, 2024
    Assignees: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON-INSTITUT DE RECERCA, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED
    Inventors: Ramon Martí Seves, Emiliano González Vioque, Cora Blázquez Bermejo, Javier Torres Torronteras, Raquel Cabrera Pérez, Yolanda Cámara Navarro
  • Patent number: 11992500
    Abstract: Described herein is a method for treating an autoimmune disease in a patient including administering to the patient in need thereof, a pharmaceutically effective amount of an epigenetic enzyme inhibitor.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: May 28, 2024
    Assignee: RUSH UNIVERSITY MEDICAL CENTER
    Inventors: Tibor A. Rauch, Daniel M. Toth, Tibor T. Glant
  • Patent number: 11993625
    Abstract: The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: May 28, 2024
    Assignee: Pfizer, Inc.
    Inventors: Omar Khaled Ahmad, Stephen Paul Brown, Kenneth John Dirico, Russell Dushin, Gary Frederick Filzen, Sujiet Puthenveetil, Pavel Strop, Chakrapani Subramanyam, Lawrence N. Tumey
  • Patent number: 11986484
    Abstract: The present invention relates to certain cortexolone derivatives of formula (I) and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of the pharmaceutical compositions as antitumor medicinal products.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: May 21, 2024
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventor: Mara Gerloni
  • Patent number: 11986530
    Abstract: Provided is a curcumin pharmaceutical preparation that is highly water soluble, can maintain the concentration of free curcumin in the blood sufficiently high by being administered parenterally, can effectively obtain a pharmacological action of curcumin, and is highly safe. A pharmaceutical composition for parenteral administration, including a water-soluble substance conjugate of curcumin as an active component.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: May 21, 2024
    Assignees: THERABIOPHARMA INC., KYOTO UNIVERSITY
    Inventors: Hideaki Kakeya, Masashi Kanai, Nobuaki Takahashi, Tadashi Hashimoto, Atsushi Imaizumi, Hitomi Ozawa
  • Patent number: 11980667
    Abstract: Trans-activating transcription (TAT) factor peptide oligomers coupled with functional agents can selectively complex to the anionic surface of cancerous cells. The TAT conjugates can be delivered to the locus of the tumors using intra-arterial injection during transient blood flow arrest.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 14, 2024
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Shailendra Joshi
  • Patent number: 11975976
    Abstract: A process for removing metallic impurities from halogenated silicon compounds, such as chlorosilane monomers and/or chlorinated polysilanes is disclosed. The process involves treating a halogenated silicon compound with a tertiary amine and thereafter a suitable grade of activated carbon.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: May 7, 2024
    Assignee: Dow Silicones Corporation
    Inventors: Reza Hagh Panah, Michael Depierro, Barry Ketola
  • Patent number: 11969437
    Abstract: The present invention provides a ready-to-use sterile alginate aqueous solution preparation which is packed in a sealed container or an airtight container and which has storage stability, comprising: (a) a low-endotoxin monovalent metal salt of alginic acid having a weight average molecular weight of 50,000 to 400,000 by a GPC-MALS method; (b) a salt selected from a monovalent metal salt and an ammonium salt; and (c) water, wherein a concentration of the component (a) is 1.5% by mass or more, a concentration of the component (b) is 0.5 to 2% by mass, and a viscosity measured at 20° C. using a rotational viscometer is 2700 mPa·s or more, and a method of producing the same. This alginate aqueous solution preparation is a ready-to-use aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: April 30, 2024
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shuichi Endo, Motoi Nakahara
  • Patent number: 11970436
    Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: April 30, 2024
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Thomas Chen, Daniel Levin, Satish Puppali
  • Patent number: 11965062
    Abstract: The method of preparing the polycarbonate ether polyol or high molecular weight polyether carbonate using controlled addition of materials during polymerisation includes the steps of: mixing catalyst of formula(I), double metal cyanide (DMC) catalyst and optionally carbon dioxide and/or solvent with epoxide and optionally starter compound and/or carbon dioxide; or mixing DMC catalyst and optionally starter compound, carbon dioxide and/or solvent with epoxide and optionally carbon dioxide and/or solvent; or mixing epoxide, catalyst of formula(I), starter compound and carbon dioxide and optionally solvent; or mixing catalyst of formula (I), DMC catalyst and optionally starter compound, epoxide, carbon dioxide and/or solvent to form in each case a mixture (?); and adding one or more of starter compound, epoxide, carbon dioxide, catalyst of formula(I), DMC catalyst and/or solvent to mixture (?) to form mixture (?) comprising starter compound, epoxide, carbon dioxide, catalyst of formula(I), DMC catalyst and optio
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: April 23, 2024
    Assignee: Econic Technologies LTD.
    Inventors: Michael Kember, James Leeland, Rakibul Kabir, Emmalina Hollis
  • Patent number: 11964023
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: April 23, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • Patent number: 11957652
    Abstract: Compositions contain citrulline and leucine or a metabolite thereof, such as hydroxyisocaproic acid (HICA) or beta-hydroxy-beta-methylbutyrate (HMB), including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for treatment of pre-diabetes, metabolic syndrome, or diabetes.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: April 16, 2024
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Christophe Moinard, Gabrielle Ventura, Denis Breuille, Christian Darimont-Nicolau, Luc Cynober
  • Patent number: 11957650
    Abstract: A formulation and a method for treating, preventing or ameliorating or alleviating in a patient the symptoms of hangover, or veisalgia, associated with a bout of excessive alcohol consumption are disclosed. More specifically, a formulation comprising L-cysteine, thiamine and pyridoxine and a method for treating, preventing, ameliorating, or alleviating in a patient one or more of the symptoms of nausea, headache, diminished concentration, malaise and/or tiredness, and a desire to consume greasy and/or fatty and/or oily foods, associated with a bout of excessive alcohol consumption are disclosed.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: April 16, 2024
    Assignee: PHOENIX PHARMACEUTICALS AUSTRALIA PTY LTD
    Inventors: Laurence Guy Howes, Jan Beatrice Quinton
  • Patent number: 11945825
    Abstract: The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: April 2, 2024
    Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Kyle Hoehn, Brandon Kenwood
  • Patent number: 11931373
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: March 19, 2024
    Assignees: University of South Florida, University of Kansas
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • Patent number: 11925660
    Abstract: A treatment for obesity can include: providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together; and administering the superabsorbent material to a subject in an effective amount to provide a treatment for obesity in the subject. The treatment can include at least one of: reducing weight of the subject; reducing rate of weight gain in the subject; or increasing rate of weight loss in the subject. The treatment of obesity can include at least one of: reducing caloric intake into the subject; reducing caloric absorption by the gut of the subject; absorbing caloric material from the gut of the subject into the superabsorbent material; or increasing transfer of caloric material from bloodstream into gut.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: March 12, 2024
    Inventor: Lijun Sun